Tagged with P

Industrial Biotech Prior to joining Life Sciences Ontario (LSO), you served as CEO of GSK Canada for a number of years. What opportunities did you see in making the switch from an MNC to an association? Having been in the pharmaceutical business for my entire career in Canada, I have always been…

Burrill & Company The managing director of Burrill & Company discusses the biotech industry in Taiwan, the various hurdles the market faces and why there is so much potential for industry growth in Taiwan. During the six years that you have been with Burrill, you have mostly covered the Greater China region. What…

R&D The president of Sanofi Pasteur Canada discusses the greatest challenges currently facing vaccine companies in Canada, and the added value that Canada’s R&D framework brings to a vaccine company like Sanofi Pasteur. What are the greatest challenges of the vaccine industry in Canada today? The biggest challenge is keeping ahead…

Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…

In-licensing An expert perspective on the possibilities of self-pay markets in Taiwan, and the opportunities afforded by bringing manufacturing of medical technology to the country, for export to the region. Uni-Pharma was founded in 1998, shortly after Taiwan introduced its national health insurance system. How was the business evolved over the…

Government Regulation You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is a highly developed economy to start with; it is a very established market, with a very good healthcare system. The…

Generics In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths, and talks about the opportunities in Asia for companies that have followed a similar path to TTY. To read the…

Hsinchu Science Park The Director General of one of the world’s most successful science parks discusses the history of the park, the reasons behind its incredible success, the unique set-up of the park which allows its administation board to act as a one-stop shop for tenants in terms of regulation and approvals, and…

Department of Investment Services The General Director of the ‘Invest in Taiwan’ program discusses Taiwan’s competitiveness on a global and regional level, highlights the areas and industrial sectors where the country is looking to invest, and talks about the importance of further economic integration with its neighbours in order to realize its potential. Can…

investment In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and biotech companies over the last fifteen years, and goes in-depth into the company’s innovative pipeline, including UBI’s possible HIV cure.…

Inlicensing The General Manager of OBI Pharma, a biopharmaceutical company currently working on a breast cancer drug, offers perspectives on developing a successful biotech company in Taiwan, the overall drug development ecosystem in Taiwan, and the acquire-develop-transfer model of doing business. Throughout our interviews in Taiwan, several industry stakeholders have expressed…

Generics Janssen has historically had a very strong focus on emerging markets. In today’s world, where growth for the pharmaceutical industry overwhelmingly comes from emerging markets, where do we find the Nordics?  What is the relevance of the Nordics for the country’s global footprint?  Jansen has preserved the cluster model. We…